drugset / Trial / NCT02427893
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Phase 3
Withdrawn
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor), administered alone and in combination, to patients with advanced BRAF V600E/K mutant melanoma.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-11
- Completion
- 2016-11
Outcome
Outcome not reported
Stopped (Enrollment): “no patients were enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cobimetinib | Small molecule | — | — |
| Comparator | Vemurafenib | Small molecule | — | Oral |